2 weeks Ago By GuruFocus.com
In This Article: Release Date: February 10, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript . Positive Points Negative Points Q & A Highlights Q : Can you discuss the potential of ARO-INHBE in obesity treatment and its role as a standalone or combination therapy? A : James Hamilton, Chief of Discovery and Translational Medicine, explained that ARO-INHBE is being studied both as a monotherapy and in combination with tirzepatide. The development path will depend on the data outcomes, and there is no specific target to hit at this stage.
The obesity market is diverse, and Arrowhead is developing a suite of drug candidates to address various needs..
